Latest News for: UCB
Edit
Caledonian Record
17 Dec 2025
UCB’s Bimzelx Continues to Shift Biologic Treatment Patterns in Hidradenitis Suppurativa as
EXTON, PA, Dec.
Edit
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Pharmiweb 10 Dec 2025
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with ...
Edit
Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights
PR Newswire 09 Dec 2025
Acquisition of Rights as Licensor and Manufacturer of Staccato® alprazolam Under a Global Partnership With UCB ... UCB acquired Engaged Therapeutics, Inc ... https.//www.ucb.com/newsroom/press-releases.
Edit
Understanding the full impact of CDKL5 deficiency disorder (UCB SA)
Public Technologies 08 Dec 2025
) ... Onset of the disease typically begins in infancy, usually during the first three months of life, and persists into adulthood ... UCB SA published this content on December 08, 2025, and is solely responsible for the information contained herein ... (noodl.
Edit
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces ...
Canada Newswire 08 Dec 2025
Edit
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder (UCB SA)
Public Technologies 08 Dec 2025
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with ...
Edit
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
PR Newswire 08 Dec 2025
Edit
The Daily Times
05 Dec 2025
UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
Edit
UCB Upgrades 2025 Financial Guidance Based on Strong Performance (UCB SA)
Public Technologies 05 Dec 2025
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with ...
Edit
UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting (UCB SA)
Public Technologies 04 Dec 2025
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with ...
Edit
UCB's unwavering commitment to shaping the future of Hidradenitis Suppurativa (UCB SA)
Public Technologies 03 Dec 2025
At UCB, we imagine an HS-free world, with a view to revolutionise science, redefine care and restore humanity ... UCB SA published this content on December 03, 2025, and is solely responsible for the information contained herein.
Edit
Citizen Health Joins Forces with UCB to Accelerate Drug Development across Epilepsy and Rare Diseases
Nasdaq Globe Newswire 02 Dec 2025
The multi-year partnership launches with focus on epilepsy, rare disease and AI. The multi-year partnership launches with focus on epilepsy, rare disease and AI ... .
Edit
The Eagle-Tribune
02 Dec 2025
Citizen Health Joins Forces with UCB to Accelerate Drug Development across Epilepsy and Rare
Edit
United Community Banks (UCB) Maintains $0.25 Quarterly Dividend, Signaling Enduring Financial Strength
The Call 13 Nov 2025
UCB) has announced a quarterly cash dividend of $0.25 per share, payable on January 5, 2026, to shareholders of record as of December 15, 2025 ... UCB) was modestly positive ... UCB) decision to maintain its ...
- 1
- 2
- Next page »